The Biopharma Pod podcast

Immunocore CEO: 3rd Big Pharma Eying Unique Cancer Targeting Tech

0:00
5:10
Rewind 15 seconds
Fast Forward 15 seconds
Immunocore is looking for more licensees for its cancer targeting technology following recent discovery and development deals with GSK and Genentech.

More episodes from "The Biopharma Pod"